All In Biotech

Drug Trial Radar · NCT07155187

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

490

Planned (sponsor's estimate)

Start

Dec 10, 2025

Primary completion

Sep 2030

Study completion Sep 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to standard of care (SOC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. This study will be divided into two stages, in the first stage (phase 2) participants will receive 1 of 2 doses of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib. In the second stage (phase 3) participants will receive the recommended phase 3 dose (RP3D) of telisotuzumab adizutecan, from the previous stage, or SOC. Approximately 490 adult participants with NSCLC will be enrolled in the study in 200 sites around the world. In phase 2, participants will receive 1 of 2 intravenous (IV) doses of telisotuzumab adizutecan as a monotherapy or in combination with oral osimertinib. In phase 3, participants will receive the IV RP3D of telisotuzumab adizutecan, or SOC. The study will run for a duration of approximately 69 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • Non-Small Cell Lung Cancer
  • c-MET

Interventions

  • Telisotuzumab AdizutecanDrug

    Intravenous (IV) Infusion

  • Standard of CareDrug

    Standard of Care

  • OsimertinibDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Objective Response (OR) Assessed by the Blinded Independent Central Review (BICR)Time frame: Up to Approximately 69 Months
  2. Phase 3: Progression-Free Survival (PFS) as assessed by the BICRTime frame: Up to Approximately 69 Months

Locations

117 sites in 20 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group - Springdale /ID# 277132

    Springdale, Arkansas · Recruiting

  • City of Hope National Medical Center /ID# 277005

    Duarte, California · Recruiting

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928

    Irvine, California · Recruiting

  • UC San Diego Health - Moores Cancer Center /ID# 278836

    La Jolla, California · Recruiting

  • Cancer Specialists of North Florida /ID# 277332

    Jacksonville, Florida · Recruiting

  • Cancer Care Centers of Brevard- Rockledge /ID# 277853

    Rockledge, Florida · Recruiting

  • Moffitt Cancer Center /ID# 276785

    Tampa, Florida · Recruiting

  • Parkview Research Center /ID# 277651

    Fort Wayne, Indiana · Recruiting

  • HealthPartners Cancer Research Center /ID# 277339

    Saint Louis Park, Minnesota · Recruiting

  • Nho - Revive Research Institute /ID# 277569

    Lincoln, Nebraska · Recruiting

  • Dartmouth-Hitchcock Medical Center /ID# 277673

    Lebanon, New Hampshire · Recruiting

  • Astera Cancer Care /ID# 277570

    East Brunswick, New Jersey · Recruiting

  • Tennessee Cancer Specialists - Knoxville - Old Weisgarber Road /ID# 277891

    Knoxville, Tennessee · Recruiting

  • SCRI Oncology Partners /ID# 276959

    Nashville, Tennessee · Recruiting

  • Fred Hutchinson Cancer Center. /ID# 277939

    Seattle, Washington · Recruiting

  • Northwest Cancer Specialists - Vancouver /ID# 277855

    Vancouver, Washington · Recruiting

  • Canberra Hospital /ID# 277166

    Garran, Australian Capital Territory, Australia · Recruiting

  • St George Hospital - Kogarah /ID# 277168

    Kogarah, New South Wales, Australia · Recruiting

  • Mater Misericordiae /ID# 276985

    South Brisbane, Queensland, Australia · Recruiting

  • Icon Cancer Centre Hobart /ID# 277549

    Hobart, Tasmania, Australia · Recruiting

  • St Vincent's Hospital Melbourne /ID# 277002

    Fitzroy, Victoria, Australia · Recruiting

  • Sunshine Hospital /ID# 276894

    St Albans, Victoria, Australia · Recruiting

  • One Clinical Research - Nedlands /ID# 277598

    Nedlands, Western Australia, Australia · Recruiting

  • Klinik Floridsdorf /ID# 276679

    Vienna, State of Vienna, Austria · Recruiting

  • Groupe Sante CHC - Clinique du MontLegia /ID# 278951

    Liège, Belgium · Recruiting

  • Institut Jules Bordet /ID# 277283

    Anderlecht, Brussels Capital, Belgium · Recruiting

  • Grand Hopital de Charleroi - Les Viviers /ID# 277282

    Charleroi, Hainaut, Belgium · Recruiting

  • Jessa Ziekenhuis - Campus Virga Jesse /ID# 277202

    Hasselt, Limburg, Belgium · Recruiting

  • Universitair Ziekenhuis Leuven /ID# 276874

    Leuven, Vlaams-Brabant, Belgium · Recruiting

  • William Osler Health System - Brampton Civic Hospital /ID# 277798

    Brampton, Ontario, Canada · Recruiting

  • Guangdong Provincial People's Hospital /ID# 277631

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Nanchang University - Xianghu Campus /ID# 277491

    Nanchang, Jiangxi, China · Recruiting

  • Shanghai Pulmonary Hospital /ID# 277488

    Shanghai, Shanghai Municipality, China · Recruiting

  • Xinjiang Medical University Cancer Hospital - Urumqi /ID# 277638

    Ürümqi, Xinjiang, China · Recruiting

  • Assistance Publique Hopitaux de Marseille - Hopital Nord /ID# 277288

    Marseille, Bouches-du-Rhone, France · Recruiting

  • CHU Brest - Hopital de la Cavale Blanche /ID# 277883

    Brest, Finistere, France · Recruiting

  • CHU de Lille - Institut Coeur Poumon /ID# 276868

    Lille, Hauts-de-France, France · Recruiting

  • Hopital Arnaud de Villeneuve /ID# 276872

    Montpellier, Herault, France · Recruiting

  • Institut Curie /ID# 277623

    Paris, Île-de-France Region, France · Recruiting

  • Universitaetsklinikum Hamburg-Eppendorf /ID# 276869

    Hamburg, Germany · Recruiting

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.